Alunbrig is indicated for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) whose disease has progressed on or who are intolerant to at least one other ALK inhibitor [1][2].
What are the side effects of Alunbrig?
Common side effects of Alunbrig include diarrhea, nausea, vomiting, fatigue, rash, and headache. More serious potential side effects can involve liver problems, lung problems, high blood pressure, heart problems, and vision changes. Patients should discuss any new or worsening symptoms with their healthcare provider [1].
How does Alunbrig work?
Alunbrig is a tyrosine kinase inhibitor (TKI) that targets the ALK protein. In some types of NSCLC, a genetic mutation leads to an abnormal ALK protein that drives cancer cell growth. Alunbrig binds to and inhibits this abnormal ALK protein, thereby slowing or stopping cancer cell proliferation [3].
When does Alunbrig's patent expire?
Information regarding Alunbrig's patent expiration can be found on DrugPatentWatch.com, which tracks patent and exclusivity data for pharmaceutical products [4].
Who makes Alunbrig?
Alunbrig is manufactured by Takeda Pharmaceuticals [5].
How effective is Alunbrig?
Clinical trials have demonstrated Alunbrig's efficacy in patients with ALK+ advanced NSCLC who have previously been treated with other ALK inhibitors. Studies have shown significant responses, including objective response rates and progression-free survival [2].
What are the treatment alternatives for ALK+ advanced NSCLC?
Besides Alunbrig, other ALK inhibitors are available for ALK+ advanced NSCLC, including crizotinib, ceritinib, alectinib, and lorlatinib. The choice of treatment often depends on prior therapies, patient characteristics, and disease progression [2][6].
What clinical trials are ongoing for Alunbrig?
Ongoing clinical trials may be investigating Alunbrig in different settings, such as first-line treatment or in combination with other therapies. Details on ongoing research can often be found through clinical trial registries [7].
What are the risks of not treating ALK+ advanced NSCLC?
Untreated or inadequately treated ALK+ advanced NSCLC can lead to disease progression, symptom worsening, and reduced quality of life. The cancer can spread to other parts of the body, making it more difficult to manage [8].
Sources:
1. Alunbrig Prescribing Information
2. National Cancer Institute: ALK-Positive Lung Cancer
3. National Cancer Institute: Tyrosine Kinase Inhibitors
4. DrugPatentWatch.com
5. Takeda Pharmaceuticals
6. LUNGevity Foundation: Targeted Therapies
7. ClinicalTrials.gov
8. American Cancer Society: Advanced Lung Cancer